Fundings for medical technology in May 2014 by mid-month have already reached $566 million, led by the $120 million raised by K2M Group Holdings in its initial public offering. Below is a list of the month’s top fundings to date:
K2M Group Holdings, Inc., has closed a $120 million initial public offering, according to the company
Minimally invasive spine technologies
TransEnterix has raised $52.2 million in a public offering according to the company
Robotic surgical system
Synthetic Genomics, Inc. (SGI), has received a $50 million investment by Lung Biotechnology Inc., a subsidiary of United Therapeutics Corporation, according to SGI.
Humanized pig lungs for transplant
Inspire Medical Systems, Inc., has raised $40 million in a Series E round of funding according to press reports
Implanted device for select patients with obstructive sleep apnea
NeoStem, Inc., has raised $38 million in a round of funding according to a regulatory filing
Cell based therapeutics to prevent, treat, cure, or regenerate damaged or aged tissue, cells and organs
GI Dynamics, Inc., has raised $31.7 million in a round of funding according to the company
Gastric sleeve for the treatment of obesity
EndoGastric Solutions, Inc., has raised $30 million in a Series G round of funding according to the company
Endoluminal reconstruction for treatment of GERD
For the complete list of medtech fundings during May 2014, see link.
For a full list of the fundings in medtech, by month, since 2009, see link.
Aesthetic and reconstructive surgery has been undergoing a transformation over the past ten years. A wide range of forces are changing the dynamics of clinical practice and the market for products used. The drivers and limiters behind this have been and, to some degree, will continue to be:
Aesthetic or purely cosmetic procedures are growing among all demographics (male/female, old/young).
The economic hits of the 2008 recession were severe, especially for aesthetics, but have begun to be replaced by new procedure volumes.
Aesthetics have become a more complex clinical practice employing surgery, a wide range of implant types and materials, topicals and physician driven procedures.
Reconstructive medicine has advanced through developments in autologous tissue engineering, extracellular matrices, and other technologies that address bone defects and other orthomusucloskeletal problems.
The advances in reconstructive medicine have begun to trickle-down to aesthetic procedures, stimulating increasingly volume of cosmetic procedures paid out-of-pocket.
There has been a series of shifts in aesthetics/reconstruction procedure volumes commensurate with these and other forces. The result is a wide swing in procedure volumes over the past decade, much of which is expected to continue. See the table below.
Percent Change in Aesthetic/Reconstructive Procedures, 2002 to 2012
Other forces behind transformation in aesthetics and reconstruction are fundamental advances in cell biology, continued progress in biomaterials development, advances in wound sealants, glues and wound closure, and others.
The topics in this post are the subject of the comprehensive MedMarket Diligence report, “Global Markets for Products and Technologies in Aesthetic and Reconstructive Surgery, 2013-2018.” See link for further details.
See also the December 2015 report, “Worldwide Wound Management, Forecast to 2024: Established and Emerging Products, Technologies and Markets in the Americas, Europe, Asia/Pacific and Rest of World”, Report #S251.
The sheer number of products in wound management provides many options for the clinician in deciding what is suitable per patient, but the choices also set up a challenge. Considering dressings alone, clinicians must match the balance of the properties of each wound and its needs for healing with the right type of dressing. Although there are hundreds of dressings to choose from, all dressings fall into a few select categories. Dressings within a particular category can then be chosen according to availability and familiarity.
Composite, or combination dressings may be used as the primary dressing or as a secondary dressing. These dressings may be made from any combination of dressing types, but are merely a combination of a moisture retentive dressing and a gauze dressing. Use on: a wide variety of wounds, depending on the dressing. These products are widely available and simple for clinicians to use. However, these may be more expensive and difficult to store, affording less choice/flexibility in indications for use.
Other dressings available on the market include dressings containing silver or other antimicrobials, charcoal dressings and biosynthetic dressings.
Traditional gauze dressings are the least occlusive type of dressing and would lie at one extreme of the continuum. Then, in order of increasing occlusion would follow calcium alginate, impregnated gauze, semi-permeable film, semi-permeable foam, hydrogels, hydrocolloids, and finally latex as the most occlusive dressing type.
Most wounds can be managed the use of different dressing types, even multiple types as the wound slowly heals and demands different conditions for optimal healing. However, due to patient status (e.g., age, circulatory status, presence of concomitant conditions like diabetes, etc.) a growing number of wounds become non-healing or simply chronic, demanding more sophisticated intervention to be healed (see link for discussion of the factors affecting wound healing). For this reason, a range of new technologies have been introduced, with others in development, to address the deficiencies in traditional wound management approaches.
The range of wound products that are in use or under development are illustrated in the following table.
See also the October 2015 report, “Worldwide Wound Management, Forecast to 2024: Established and Emerging Products, Technologies and Markets in the Americas, Europe, Asia/Pacific and Rest of World”, Report #S251.
Wound management is a field and an industry in a constant state of flux. With so many different technologies involved in addressing wounds, from the chronic to the acute, with technologies from the very well established to the cutting-edge new, the balance of product utilization (and manufacturer revenues) is a constantly moving target.
Traditional wound dressings — simple gauze or other inert bandages — represent a huge existing market by virtue of their broad clinical utility and well established presence in the market (literally, centuries), while novel technologies like growth factors, which have just begun to demonstrate their potential to accelerate healing and/or solve the vexing problem of chronic wounds, have not really begun to penetrate clinical practice and generate substantial caseloads, yet. Between the extremes is a continuous range of products across the spectrum from the established to the novel.
Below is illustrated the 2012 to 2021 shift in the balance of the global wound management products market for the specific product types. The aggregate market is growing over this period at a respectable +7% CAGR, but that aggregate rate belies the individual segment rates ranging from a low of under 2% to a high of over 27%. That makes these share values all the more intriguing.
See also the October 2015 report, “Worldwide Wound Management, Forecast to 2024: Established and Emerging Products, Technologies and Markets in the Americas, Europe, Asia/Pacific and Rest of World”, Report #S251.
A delicate physiological balance must be maintained during the healing process to ensure timely repair or regeneration of damaged tissue. Wounds may fail to heal or have a greatly increased healing time when unfavorable conditions are allowed to persist. An optimal environment must be provided to support the essential biochemical and cellular activities required for efficient wound healing and to remove or protect the wound from factors that impede the healing process.
Factors affecting wound healing may be considered in one of two categories depending on their source. Extrinsic factors impinge on the patient from the external environment, whereas intrinsic factors directly affect the performance of bodily functions through the patient’s own physiology or condition.
These are discussed in detail in “Wound Management, Worldwide Market and Forecast to 2021: Established and Emerging Products, Technologies and Markets in the Americas, Europe, Asia/Pacific and Rest of World.” Report #S249.
(See the 2016 published report #S290, “Sealants, Glues, Hemostats, 2016-2022”.)
Surgical closure and securement products range from simple suture products to sophisticated biomaterial aids for hemostasis, sealant activity, and for adhesion prevention. Within the hemostasis field, products have the objective of rapidly achieving hemostasis and acting to seal in the presence of high pressure blood flow or air flow.
Natural hemostats such as gelatin, collagen and thrombin were first developed as hemostatic agents, followed by mixes and fibrin sealants. More recently, companies have introduced synthetic sealants and hemostats that accelerate the process of blood clotting and provide a stronger seal that will withstand greater pressures. These products employ various synthetic polymer chemistry systems. Glues are required to secure tissue firmly under substantial forces. In extreme cases such as musculoskeletal repair, these glues need to withstand high tension and pressure forces. Fibrin and other sealants are not strong enough for these applications and have been used as adjuncts to sutures and staples. Cyanoacrylate glues have sufficient strength for most procedures but are not yet cleared for use in the majority of internal applications due to toxicity concerns. They also lack sufficient flexibility for use in many procedures.
Efforts are progressing to develop new biomaterials capable of gluing tissues with high strength, low toxicity, and sufficient flexibility to avoid breakage of the bond. In addition, cyanoacrylate manufacturers are examining the possibility of improving cyanoacrylate technology to overcome the existing challenges of toxicity and brittleness. Despite this huge challenge, one or both of these two approaches are likely to establish new products in the next decade. In addition, the evidence of research work suggests it should be possible to create a glue technology that incorporates hemostatic properties to further enhance the role of this technology.
Apart from fibrin-based sealants and cyanoacrylate-based high-strength glues, there are three other main categories of closure/attachment products in use or in development at present.
Collagen and Thrombin Combination Collagen is a major protein found in most mammals; the form of collagen that is generally used for wound sealant and closure is a white water-soluble fiber containing several key amino acids. In most sealants, collagen forms a matrix on which thrombin (but also fibrin, polyethylene glycol (PEG) polymers, or other compounds) are attached. The role of the collagen matrix is to channel blood with its various clotting proteins to the compounds attached to the matrix (thrombin, etc.), triggering a clotting cascade.
Polyethylene Glycol Polymer (PEG) Polymers such as polyethylene glycol polymer (PEG) can absorb fluids and are the basis for products to seal and join tissues. CoSeal (Angiotech Pharmaceuticals, marketed by Baxter BioSurgery) and FocalSeal (Genzyme) are two products of this type. They are completely synthetic and offer quick sealing of the wound with the flexibility to expand and contract. Because these sealants are synthetic, they do not pose the risk of viral infection spreading from one person to another.
Albumin Cross-Linked with Glutaraldehyde Albumin, the protein that forms egg white, is one of the strongest natural adhesives in the market. Albumins are water-soluble and will coagulate when heated or combined with certain acids. When combined with glutaraldehyde, albumin forms a strong adhesive for internal surgery. The albumin/glutaraldehyde compound forms a cross-link with the tissues to be bonded that can even be stronger than the underlying tissues. In fact, the compound has been shown to withstand pressures of 500 mm–800 mm of mercury, which is more than four times normal human blood pressure.
CryoLife’s BioGlue is a widely used albumin/glutaraldehyde glue. It begins to set within 20–30 seconds of application and reaches its ultimate bonding strength within two minutes.
It is unlikely that any one formulation of tissue glue will be adequate for all applications. For example, fixing fragments of bone after significant bone trauma is likely to require an adhesive with a different modulus and strength to that required for adherence of pericardium during cardiovascular surgery. It is also likely that the sealant and hemostatic properties of these two products will need to be different. For example, to stick pericardial tissues together, the surgeon will be concerned with avoiding surgical adhesions and excessive fibrosis that might lead to problems during revision surgery. In the example of bone repair, rapid rehabilitation and avoidance of non-unions during fracture healing is a major challenge: this would suggest looking for a glue that encourages osteoblast activity and does not form an impenetrable barrier for cellular in- growth, but which can also tolerate the static and dynamic forces put upon bone.
Recently, new technologies have appeared on the market to address the need for adhesion prevention. These products have been formulated to be approvable by the FDA through device regulation routes; thus, in addition to providing a physical barrier, these products also may have some subsidiary active mechanism to achieve their objective.
In parallel with new products, in several instances new delivery systems have had to be developed. Surgeons also experiment with these products in an effort to produce superior results. A surgeon may, for example, mix a sealant with a few ml of saline to gain greater control over product application. Development of these delivery systems may be driven by several factors, such as: to improve the speed and ease of surgical procedures; to facilitate complex procedures that would otherwise be less successful; to better access a particular tissue; or to avoid premature mixing of two components, thus providing better control of the gluing process. New delivery systems have evolved to spray liquid hemostat solutions such as thrombin onto surgical sites to improve speed of hemostasis. Fibrin sealant is supplied as two powders that need to be solubilized and then mixed immediately prior to application to the surgical site. This has led to the development of a number of sophisticated medical delivery devices, and companies like Baxter aredeveloping single component systems that are already solubilized for immediate use in the surgical theater.
Cyanoacrylate adhesive for surgical closure is a topical-only treatment that eventually sloughs off the top surface of the wound. The product is applied to the surface of the skin to form a glue film that secures apposition of the cut edges of the incision. Currently, the cyanoacrylate is supplied in a device that aids the curing of the adhesive and ensures its safe handling and application.
Several fairly sophisticated delivery systems for new sealant and glue products have been developed or are currently under development. As new procedures are developed for cyanoacrylate and new glues, new devices will be required to aid the procedure. The devices will contribute an increasing proportion of the value associated with the gluing process.
Sophisticated surgical instruments are being developed to facilitate the application in each new indication for new high-strength glue products. High-strength glues are increasingly being utilized to repair vascular joints in coronary bypass operations. Customized instrumentation is designed to hold vessels in place and facilitate the application of exact amounts of adhesive and to avoid subsequent delays from leakage, or imperfect integration of the grafted tissues.
The market for tissue engineering and cell therapy products is set to grow from a respectable $8.3 billion in 2010 to nearly $32 billion by 2018. This figure includes bioengineered products that are themselves cells or are actively stimulating cell growth or regeneration, products that often represent a combination of biotechnology, medical device and pharmaceutical technologies. The largest segment in the overall market for regenerative medicine technologies and products comprises orthopedic applications. Other key sectors are cardiac and vascular disease, neurological diseases, diabetes, inflammatory diseases and dental decay and injury.
Factors that are expected to influence this market and its explosive growth include political forces, government funding, clinical trial results, industry investments (or lack thereof), and an increasing awareness among both physicians and the general public of the accessibility of cell therapies for medical applications. Changes in the U.S. government’s federal funding of embryonic stem cell research has given a potentially critical mass of researchers increased access to additional lines of embryonic stem cells. This is expected to result in an increase in the number of research projects being conducted and thus possibly hasten the commercialization of certain products.
Another factor that has influenced the advancement of regenerative technologies is found in China, where the Chinese government has encouraged and sponsored cutting-edge (and some have complained ethically questionable) research. While China’s Ministry of Health has since (in May 2009) established a policy requiring proof of safety and efficacy studies for all gene and stem cell therapies, the fact remains that this research in China has spurred the advancement of (or at least awareness of) newer applications and capabilities of gene and stem cell therapy in medicine.
Meanwhile, stricter regulations in other areas of Asia (particularly Japan) will serve to temper the overall growth of commercialized tissue and cell therapy–based products in that region. Nonetheless, the growth rate in the Asia/Pacific region is expected to be a very robust 20% annually.
MedMarket Diligence’s Report #S520 remains the most comprehensive and credible study of the current and project market for products and technologies in cell therapy and tissue engineering.
Since January 1 of this year, we have identified 42 medical technology startups and added them to the Medtech Startups Database. As is the case with all of the companies in this database, these recently added companies represent a wide range of focus in clinical practice and technology:
(Note: Multiple categories possible per company, such as minimally invasive and surgery)
Source: MedMarket Diligence, LLC
Below is a list of the technologies under development by these startups:
Ophthalmology prescreening technology for detection of diabetic retinopathy, cataract, glaucoma, cornea problems and refractive errors
Tissue engineered scaffolds to generate synthetic tracheas
Resorbable embolization material for use in interventional radiology and drug delivery.
Time-varying electromagnetic fields for the treatment of inflammatory, autoimmune and degenerative diseases
Tissue attachment technology
Devices and procedures to improve nasal breathing
Devices for minimally invasive, augmentative or reconstructive mastopexy
Ocular stent for treating age-based vision changes
Ophthalmic device company focusing on age-related macular degeneration, diabetic retinopathy, retinitis pigmentosa, hemianopia, and glaucoma
Neuroscience-based technology (neuromodulation) for enhancing performance on cognitive tasks, for the healthy and impaired
Portable, ultrasound-based device non-invasive, transcranial diagnosis of stroke
Temporary cardiac pacing as treatment for reversible symptomatic bradycardia
Product to improve treatment of kidney stones and product to reduce pneumonia in intubated patient and ventilated patients in the ICU
Biometric medical device for orthopedic and other diagnostic applications
Technologies for treating urological conditions and disorders
Use of biomaterials in aesthetics for non-surgical temporary & permanent breast and buttock enhancement, facial rejuvenation solutions and adipose tissue engineering related therapies
Custom surgical implants including using 3D printing
Targeted, localized drug delivery
Protein-free tissue sealants in surgery, initially targeted to vascular applications
Hemostatic dressing for non-compressible hemorrhage
High resolution imaging in cancer
Cardiac assist device for patients otherwise needing transplant
Implant to restore some sight for patients with retinitis pigmentosa
Device to harvest bone grafts
Device and method for self-collection of samples to screen for HPV, chlamydia, and gonorrhea
Implantable neuromodulation device for the treatment of chronic pain and overactive bladder
Encapsulated pancreatic cells for treatment of type 1 diabetes
Deep brain stimulation for Alzheimer’s and other cognitive disorders.
Magnetoencephalography and magnetocardiography
Technologies to manage core temperature in critical care and post-surgical patients
New method to use pulse wave velocity to measure arterial stiffness as indicator of heart attack risk
Autologous cell therapy delivered at the intraoperative point of care
Minimally invasive hip implants and other orthopedic implants
Tactile stimulator to work with fMRI, a dermatome for skin grafts and other technologies
Carbon nanotube fiber material to treat ventricular arrhythmia
Devices for cardiac and vascular procedures designed for easier use and lower cost
Knotless suture technology
For a historical list of technologies at medtech startups in the full database, see link.
Global medical aesthetic products are to achieve sales of more than $6.5 billion in 2013. Through 2018 the market is expected to reach a value of about $10.7 billion. Europe has been witnessing relatively a slower growth of 6.6% per year. Declining purchasing power, particularly in southern Europe affects the European market and this geographical segment is estimated at $1.84 billion in 2013 to reach $1.94 billion in 2018. The U.S. and the Latin America markets will have a CAGR close to 10%. The U.S. and Latin America will experience a growth respectively of 9.2% and 10% in line with global trends. The U.S. market still represents 45% of the global market.
The Asia/Pacific region will have an overall CAGR of more than 14.1%. Asia will experience the strongest growth through 2018 and exceed the level of the European market in 2018 to $2.24 billion. Overall, the annual growth of the world market between 2013 and 2018 should be 10% to $10.7 billion.
The injectable products (botulinum toxin and fillers mainly hyaluronic acid) constitute the top market segment in value and will have a CAGR of 10.8% until 2018, thus confirming their constant development potential. Since 2012, the toxins market marginally exceeded the dermal fillers market in the world but with a few exceptions such as Europe. The main markets for injectable products by decreasing order are the U.S., E.U., Asia and South America.
The energy-based devices (laser, radiofrequency, ultrasounds) will have an average CAGR of 10.3% until 2018. The sub-segment of body contouring devices will have an average CAGR of 12.1% until 2018. It should represent as nearly half of the activity-based equipment energy by 2018. The main markets for energy-based devices by decreasing order are the U.S., E.U. Asia and South America.
The cosmeceuticals (active cosmetics) will follow the same trend as the injectable products. The major markets for active cosmetics in decreasing order are the U.S., Asia, South America and the E.U. The market for active cosmetics in 2013 and 2018 will be $1,026 million and $1,677 million respectively. The breast implants will have a reduced progression of 5.2% per year until 2018. The major markets for breast implants by decreasing order are the U.S., South America, E.U. and Asia. The 2013 and 2018 market for breast implants will be about $1,066 and $1,370 million respectively. The two most popular cosmetic surgery procedures are still, in the world as well as for each geographical area, the liposuction and the breast augmentation with prosthetic implants. Breast implants experienced a slowdown of about 9% mainly due to concerns about the safety of their components, but this suspicion seems to disappear gradually in recent months.
More limited surgical procedures now are performed in the face, arm, or the internal face of thighs. The goal is primarily to make a change with a natural result. For the face it is readily associated with fat injection to recover volumes. Minimal invasive therapies enjoy a strong growth in 2013, especially with the new botulinum toxin. Alternative techniques to the toxin as cryomodulation begin to develop. The non-invasive techniques are increasingly linked to each other: toxin for the upper face and hyaluronic acid for the lower face, willingly associated with rejuvenation and retightening techniques of the skin by radio frequency and light peels. Far from being opposed to surgery, these techniques maintain surgery result. There is strong growth of surgical cosmetic procedures for men and women above 50 years old in Western countries due to the demand for anti-aging treatment and social pressure. These procedures increased from 28% to 36% between 2005 and 2011, this demand is also significant for invasive treatments and non-invasive.
From “Global Markets for Products and Technologies in Aesthetic and Reconstructive Surgery, 2013-2018”, Report #S710, published by MedMarket Diligence, LLC.